Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACTION: Nivolumab +/- Relatlimab after SBRT in Advanced Esophagogastric Cancer
NCT03610711Phase 2Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2019
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and relatlimab in gastroesophageal junction cancer (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Change in the infiltrating CD8+ T cell density units at 5 years. Started Mar 2019; status: active, not recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT03610711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610711.